The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
IHC-P: 1/50. Perform heat mediated antigen retrieval before commencing with IHC staining protocol by boiling tissue section in 10mM Citrate buffer, pH 6.0 for 10-20 min followed by cooling at RT for 20 min.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Seems to play a role in the development or function of the kidney glomerular filtration barrier. Regulates glomerular vascular permeability. May anchor the podocyte slit diaphragm to the actin cytoskeleton. Plays a role in skeletal muscle formation through regulation of myoblast fusion.
Specifically expressed in podocytes of kidney glomeruli.
Involvement in disease
Defects in NPHS1 are the cause of nephrotic syndrome type 1 (NPHS1) [MIM:256300]; also known as Finnish congenital nephrosis (CNF). A renal disease characterized clinically by proteinuria, hypoalbuminemia, hyperlipidemia, and edema. Kidney biopsies show non-specific histologic changes such as focal segmental glomerulosclerosis and diffuse mesangial proliferation. Some affected individuals have an inherited steroid-resistant form and progress to end-stage renal failure.
Belongs to the immunoglobulin superfamily. Contains 1 fibronectin type-III domain. Contains 8 Ig-like C2-type (immunoglobulin-like) domains.
In 23-week-old embryo found in epithelial podocytes of the periphery of mature and developing glomeruli.
Phosphorylated on tyrosine residues.
Cell membrane. Predominantly located at podocyte slit diaphragm between podocyte foot processes. Also associated with podocyte apical plasma membrane.